News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Amgen says it will continue to invest in manufacturing technologies to support its biosimilar pipeline despite announcing a restructuring that will reduce its manufacturing footprint by 23%.
As the US FDA (Food and Drug Administration)’s biosimilars pathway is tested for the first known time following Sandoz’s filgrastim submission last week, an expert predicts imminent biosimilars submissions from Celltrion and Hospira.
Pfizer has agreed to pay $635m (€474m) to Baxter International for its vaccine business, including two marketed products and a facility in Austria.
The worst Ebola virus outbreak in history continues to spread in West Africa as biopharma companies are hampered by funding issues in trying to bring treatments and vaccines to human trials, a scientist says.